Walenga JM, Prechel MM, Jeske WP, Bakhos M.Unfractionated heparin compared with low molecular weight heparin as related to heparin-induced thrombocytopenia. Curr Opin Pulmon Med.2005;11:385-391.
2.
Warkentin TE , Levine MN, Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin . N Engl J Med.. 1995 ;332:1330-1335.
3.
Amiral J., Peynaud-Debayle E., Wolf M., Bridey F., Vissac AM, Meyer D.Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol.1996;52:90-95.
4.
Bauer TL, Arepally G., Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation . 1997;95:1242-1246.
5.
Pouplard C., May MA, Iochmann S., et al. Antibodies to platelet factor 4-heprin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular weight heparin: clinical implications for HIT. Circulation . 1999;99:2530-2536.
6.
Lindhoff-Last E., Eichler P., Stein M., et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res.2000;97:387-393.
7.
Prechel M., Bano A., Drenth AF, Messmore HL, Walenga JMAssay selection and interpretation for laboratory testing of heparin-induced thrombocytopenia: diagnostic implications. Blood. 2001;98:36a.
8.
Gruel Y., Pouplard C., Nguyen P., et al, the French Heparin-Induced Thrombocytopenia Study Group.Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol.2003;121:786-792.
9.
Francis JL, Palmer GP III, Moroose R., Drexel A.Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg.2003;75:17-22.
10.
Gluckman TJ , Segal JB, Fredde NL, et al. Incidence of anti-platelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol.2005;95:744-747.
11.
Warkentin TE , Maurer BT, Aster RHHeparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med.2007;356:2653-2654.
12.
Ahmad S., Untch B., Haas S., et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis . Mol Cell Biochem.2004;258:163-170.
13.
Ahmad S., Haas S., Hoppensteadt DA, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res.2003;108:49-55.
14.
Ahmad S., Bacher P., Lassen MR, et al. Investigations of the immunoglobulin subtype transformation of antiheparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (Clivarin) in orthopedic patients. Arch Pathol Lab Med.2003;127:584-588.
15.
Chilver-Stainer L., Lämmle B., Alberio L.Titre of antiheparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems . Thromb Haemost.2004;91:276-82.
16.
Mattioli AV , Bonetti L., Sternieri S., Mattioli G.Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J.2000;1:39-42.
17.
Williams RT , Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation . 2003;107:2307-12
Hoppensteadt D., Jeske W., Ahsan A., Walenga J., Fareed J.Biochemical and Pharmacologic Profile of Defined Molecular Weight Fractions of Heparin. Sem Throm Hemost.1993;19:12-19.
20.
Untch B., Ahmad S., Jeske W., et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: the pathogenic role of IgG. Thromb Res.2002;105:117-123.
21.
Jeske WP, Ackerman P., Drenth A., Walenga J., Bakhos M.Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays. J Thromb Haemost.2007;5(suppl 2):P-M-647.
22.
Izban KF, Lietz HW, Hoppensteadt DA, et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25(suppl 1):51-56.
